Last reviewed · How we verify
NCT05458869
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
trial testing HPV Self-Collection in Cervical Carcinoma in 16 participants. Completed in 30 May 2023.
30 May 2023
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 6 September 2022 |
| Primary completion | 30 May 2023 |
| Estimated completion | 30 May 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HPV Self-Collection
- Interview
- Survey Administration
Conditions studied
- Cervical Carcinoma — all drugs for Cervical Carcinoma →
- Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →
Sponsor
OHSU Knight Cancer Institute
Who can join
25 and older, female only, with Cervical Carcinoma or Human Papillomavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study explores the human papillomavirus (HPV) self-collection experience among individuals with a history of sexual trauma. Cervical cancer is the fourth most common cancer in women worldwide and is the second leading cause of cancer-related death in women ages 29-39. Despite programs to improve accessibility of cervical cancer screening and overall high screening rates, disparities in routine surveillance have been demonstrated in certain populations, such as victims of intimate partner violence and sexual trauma. One barrier to participating in cervical cancer screening for this population is the office-based visit which necessitates the individual to undress, sit with their legs in stirrups, and undergo speculum examination for specimen collection. This type of visit may cause distress for participants who have experienced sexual violence. HPV self-collection has been studied with favorable outcomes in effectiveness and ease of use. This study evaluates the experience of HPV self-collection among individuals who have experienced sexual trauma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05458869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HPV Self-Collection
Trials testing the same drug.
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT07186530 — Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening · NA · enrolling by invitation
- NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
- NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
Other recruiting trials for Cervical Carcinoma
Currently open trials in the same condition.
- NCT07407647 — Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Phase 2 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05458869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 27 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05458869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing